Share this post on:

Product: Basmisanil

RHCE RNAi Summary

Specificity
Rhesus blood group, CcEe antigens (RHCE), transcript variant 4, mRNA
Gene
RHCE

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for RHCE RNAi

  • blood group Rh(CE) polypeptide
  • blood group RhCcEe antigen
  • CD240CE antigen
  • CD240CE
  • MGC103977
  • Rh blood group antigen Evans
  • Rh blood group C antigen
  • Rh blood group, CcEe antigens
  • Rh polypeptide 1
  • Rh polypeptide I
  • RH
  • RH30A
  • Rh4
  • RHC
  • RHCE blood group variant Crawford antigen Rh43
  • RHE
  • Rhesus blood group CE protein
  • Rhesus blood group E antigen
  • Rhesus blood group Rhce antigen
  • Rhesus blood group, CcEe antigens
  • Rhesus C/E antigens
  • Rhesus system C and E polypeptides
  • RhIVb(J)
  • RHIXB
  • RHPI
  • RhVI
  • RhVIII
  • silenced Rh blood group CcEe antigen

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 7617805

Share this post on:

Author: Potassium channel

Share this post on:

Product: Valspodar

RHCE RNAi Summary

Specificity
Rhesus blood group, CcEe antigens (RHCE), transcript variant 1, mRNA
Gene
RHCE

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for RHCE RNAi

  • blood group Rh(CE) polypeptide
  • blood group RhCcEe antigen
  • CD240CE antigen
  • CD240CE
  • MGC103977
  • Rh blood group antigen Evans
  • Rh blood group C antigen
  • Rh blood group, CcEe antigens
  • Rh polypeptide 1
  • Rh polypeptide I
  • RH
  • RH30A
  • Rh4
  • RHC
  • RHCE blood group variant Crawford antigen Rh43
  • RHE
  • Rhesus blood group CE protein
  • Rhesus blood group E antigen
  • Rhesus blood group Rhce antigen
  • Rhesus blood group, CcEe antigens
  • Rhesus C/E antigens
  • Rhesus system C and E polypeptides
  • RhIVb(J)
  • RHIXB
  • RHPI
  • RhVI
  • RhVIII
  • silenced Rh blood group CcEe antigen

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 18523586

Share this post on:

Author: Potassium channel

Share this post on:

Product: PCI-32766

RHCE RNAi Summary

Specificity
Rhesus blood group, CcEe antigens (RHCE), transcript variant 3, mRNA
Gene
RHCE

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for RHCE RNAi

  • blood group Rh(CE) polypeptide
  • blood group RhCcEe antigen
  • CD240CE antigen
  • CD240CE
  • MGC103977
  • Rh blood group antigen Evans
  • Rh blood group C antigen
  • Rh blood group, CcEe antigens
  • Rh polypeptide 1
  • Rh polypeptide I
  • RH
  • RH30A
  • Rh4
  • RHC
  • RHCE blood group variant Crawford antigen Rh43
  • RHE
  • Rhesus blood group CE protein
  • Rhesus blood group E antigen
  • Rhesus blood group Rhce antigen
  • Rhesus blood group, CcEe antigens
  • Rhesus C/E antigens
  • Rhesus system C and E polypeptides
  • RhIVb(J)
  • RHIXB
  • RHPI
  • RhVI
  • RhVIII
  • silenced Rh blood group CcEe antigen

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 26181372

Share this post on:

Author: Potassium channel